http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#Head
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#assertion
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#provenance
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#pubinfo
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#assertion
http://purl.obolibrary.org/obo/DOID_1920
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_1920
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB04854
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#association
http://www.w3.org/2000/01/rdf-schema#label
uloric is a xanthine oxidase xo inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol who are intolerant to allopurinol or for whom treatment with allopurinol is not advisable for the safe and effective use of allopurinol see allopurinol prescribing information uloric is a xanthine oxidase xo inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol who are intolerant to allopurinol or for whom treatment with allopurinol is not advisable 1 for the safe and effective use of allopurinol see allopurinol prescribing information limitations of use uloric is not recommended for the treatment of asymptomatic hyperuricemia 1 limitations of use uloric is not recommended for the treatment of asymptomatic hyperuricemia
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB04854
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#provenance
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#pubinfo
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#sig
http://purl.org/nanopub/x/hasSignature
gyF42SyJ4DWGVjSoJtjuz/OVtAHQe+2LpGJXBfIKceslvqwMAqVJwonY7XO9IIpnOH2dH/CoT46QNc9Q+i2PdpHBQS231SSHpT3qnIYpvhe3GpW7721ANs5DLpnWGvbUygw57sK3G1kCZOMwQEHvytYcI7kSXKVnwoPczkHK/LE=
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU
http://purl.org/dc/terms/created
2021-06-12T13:28:40.734+02:00
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs